The positive decision from the Canadian Intellectual Property Office means that the oral film technology with steroids used in AcuCort's approved drug Zeqmelit™ has patent protection. The drug's name was formerly ISICORT. The Canadian patent is co-owned with AcuCort's former manufacturing partner LTS Lohmann.

Intellectual property rights such as patent and trademark protection play a crucial role in AcuCort's future commercial opportunities. The company has an active IP strategy covering the important pharmaceutical markets. Zeqmelit™ currently has patent protection in more than 30 countries, including Europe, the U.S., Japan, China and Canada.

In the development of Zeqmelit™, AcuCort has managed to combine the benefits of the well-proven substance dexamethasone and the patented user-friendly oral film for quick availability and relief in emergency situations such as severe and acute allergic reactions. Zeqmelit™ is approved in Sweden, Denmark and Norway. The registration process for other countries within the EU is ongoing. AcuCort's overarching goal is to commercialize Zeqmelit™ globally, i.e. in the EU, the U.S. and in other priority markets.

"We are pleased that the Canadian Intellectual Property Office has granted the patent for Zeqmelit™. A strong and broad patent portfolio is also a prerequisite for future potential licenses and partnerships in the upcoming global commercialization," says Jonas Jönmark, CEO of AcuCort AB.

The information was submitted for publication, through the agency of the contact person below, on October 19, 2022.